<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281735</url>
  </required_header>
  <id_info>
    <org_study_id>CIC09-33</org_study_id>
    <secondary_id>2010-023359-27</secondary_id>
    <nct_id>NCT01281735</nct_id>
  </id_info>
  <brief_title>International Chronic Myeloid Leukemia Pediatric Study</brief_title>
  <acronym>ICMLPed</acronym>
  <official_title>INTERNATIONAL STUDY of Chronic Myeloid Leukaemia (CML) Treatment and Outcomes in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International BFM Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to describe and characterize CML in a large pediatric cohort of&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      International study of CML in children and adolescents&#xD;
&#xD;
        1. Rational and objectives 1.1 Rational: Chronic myeloid leukaemia (CML) is a malignant&#xD;
           disease of the hematopoietic system characterized by the presence a reciprocal&#xD;
           translocation between chromosome 9 and 22. CML is a very rare disease in children and&#xD;
           adolescents, accounting for 2% to 3% of leukemias in this age range, with an annual&#xD;
           incidence of 1 case per million children (1,2,3). A recent report of the French National&#xD;
           Registry of childhood leukemia and lymphoma revealed an incidence of 0.6 case per&#xD;
           million children under 15 years of age between 1990 and 1999 in France. Characteristics&#xD;
           of CML seem to differ in this age range compared with adults (5). In Europe, very few&#xD;
           children and adolescents with CML is included in national trials nor are they recorded&#xD;
           in regional or national registries. A European CML-Registry was established to improve&#xD;
           the knowledge concerning this disease but only patients aged 18 years and over are&#xD;
           registered. In Europe, a national registry was recently set up in UK to collect&#xD;
           prospectively data in patients less than 15 years of age with CML. However, limited&#xD;
           information is available concerning the epidemiology and the characteristics of CML in&#xD;
           childhood.&#xD;
&#xD;
           There are currently two main treatment options in children with CML. The first option is&#xD;
           allogeneic hematopoietic transplantation which is a potentially curative therapy in&#xD;
           children with a suitable donor. Transplantation with a matched unrelated donor resulted&#xD;
           in an overall survival rate of 66% at 3 years in children with CML in first chronic&#xD;
           phase (6). A 5-year overall survival rate of 73 % was reported in those transplanted&#xD;
           with a matched sibling donor (7). The second option is treatment with imatinib mesylate,&#xD;
           an orally administered antityrosine kinase. Imatinib mesylate is well tolerated and&#xD;
           cytogenetic and molecular remissions can be achieved in a significant percentage of&#xD;
           children with CML (8, 9). However, the ability of imatinib mesylate to cure the disease&#xD;
           remains unknown.&#xD;
&#xD;
           In adults with CML, Sokal and Hasford reported 2 distinct staging systems able to&#xD;
           distinguish patient groups with different survival. These scoring systems were&#xD;
           determined in cohorts of patients including adults and children, but the data of the&#xD;
           younger patients were not analysed separately. Moreover, the Sokal score was determined&#xD;
           in patients treated with busulfan or hydroxyurea and the Hasford score in patients&#xD;
           receiving IFN therapy. Identification of prognosis factors and determination of a&#xD;
           prognostic scoring system in children and adolescents with CML are essential to optimize&#xD;
           individual treatment strategy in this age group. All these points justify the need for&#xD;
           an international network to better describe this rare disease in children and&#xD;
           adolescents and to optimize individual treatment strategy.&#xD;
&#xD;
           1.2 Objectives.&#xD;
&#xD;
           The main objectives of the study are the followings:&#xD;
&#xD;
             -  To describe the characteristics of CML in a large cohort of patients less than 18&#xD;
                years of age&#xD;
&#xD;
             -  To describe the treatment policies.&#xD;
&#xD;
             -  To identify prognostic factors in this age-group&#xD;
&#xD;
             -  To determine prognostic scoring systems in this population in order to optimize&#xD;
                individual treatment choices.&#xD;
&#xD;
             -  To determine side effects and long term effects of treatments, mainly the tyrosine&#xD;
                kinase inhibitor effect, on growth and development of a pediatric population&#xD;
&#xD;
        2. Population. All patients less than 18 years of age with newly diagnosed Philadelphia&#xD;
           positive and/or bcr-abl positive CML are eligible whatever the phase of the disease, the&#xD;
           type of treatment and the enrollment or not in a clinical study.&#xD;
&#xD;
           However their data will be collected only if requirements concerning ethics and policy&#xD;
           agreement are fulfilled (see section 9)&#xD;
&#xD;
        3. Method The study is strictly observational. Retrospective and prospective data will be&#xD;
           collected from patient flow charts and/or existing databases.&#xD;
&#xD;
           A steering committee (SC) including A Biondi, E De Bont, MF Dresse, J de la Fuente, M&#xD;
           Suttorp, J Guilhot and F Millot will promote the international study of CML in children&#xD;
           and adolescents. The SC will include representatives of each country involved in the&#xD;
           study. The SC will agree on policy, support its implementation, initiate research, and&#xD;
           raise public awareness about the study by presentations and publications.A scientific&#xD;
           committee (SciC) will be set up. By laws regarding data property,analysis and&#xD;
           publication will be decided by the scientific committee and the steering committee. For&#xD;
           each objective of the study, there will be a working party (WP),which will be open to&#xD;
           all interested participants in the study.Data will be provided by clinicians and&#xD;
           biologists involved in pediatric haematology.The data base of the study will be set up&#xD;
           in the Clinical Investigation Center(CIC INSERM 802)of the University Hospital of&#xD;
           Poitiers(France)which will be the International Central Data Center(ICDC) of the study&#xD;
           in charge of and centralizing the data. Sophie Zin Ka Yeu will be the responsible for&#xD;
           the monitoring,E Ducasse for data base management and J Guilhot for the statistical&#xD;
           analysis. The study is international.A National Coordinating Center and a leader will be&#xD;
           identified in each participating country. The National Coordinating Center will be in&#xD;
           charge of collecting data for his country. Each leader of the National Coordinating&#xD;
           Center will be in charge of registering the patients and sending the data to the ICDC&#xD;
           (CIC INSERM 802, Poitiers, France). To avoid double entry, the location of the medical&#xD;
           center where the CML of the patient was diagnosed will be recorded in the case report&#xD;
           form. Moreover, notification of new cases may be cross checked by national coordinators&#xD;
           with their own national registry when available (for example with the Registre national&#xD;
           des hémopathies malignes de l'enfant in France).&#xD;
&#xD;
        4. Origin and type of data:&#xD;
&#xD;
           Data will include:&#xD;
&#xD;
             -  Identification number&#xD;
&#xD;
             -  Demographic data&#xD;
&#xD;
             -  Date of birth&#xD;
&#xD;
             -  Sex&#xD;
&#xD;
             -  Medical data Ethnicity will be collected because of variation in terms of clinical&#xD;
                characteristics (height for example) and pharmacokinetic of medication of the&#xD;
                different groups of children potentially involved. Identifying biological results&#xD;
                will not be collected.&#xD;
&#xD;
           The ICDC will collect only data which is strictly anonymized by the national&#xD;
           coordinating centers. Patients will be identified by a code including 2 to 3 letters for&#xD;
           the country and 4 digits for the patient number (ex: FR/0001 for the first registered&#xD;
           Patient in France). No initial of patients will be used. As country coordinator for&#xD;
           France, F Millot will also collect initials of French patients in order to avoid double&#xD;
           registration. These initials will not be computerized. The international ID number will&#xD;
           be immediately provided.&#xD;
&#xD;
        5. Circulation of the data The data is centralized in the ICDC of the study. The ICDC is&#xD;
           located in the Clinical Research Investigation Center of the University Hospital of&#xD;
           Poitiers (France).&#xD;
&#xD;
           Retrospective data:the data will be collected in a one step procedure. Prospective&#xD;
           data:The data will be collected using a two step procedures.&#xD;
&#xD;
             1. Notification of the cases:&#xD;
&#xD;
                New cases will be notified by physicians and biologists involved in pediatric&#xD;
                hematology to their National Coordinating Center; at regular intervals these cases&#xD;
                will then be referred by this coordinating center to the ICDC.&#xD;
&#xD;
             2. Full data collection:&#xD;
&#xD;
           The data will be collected from the clinical chart of the patients. The complete data&#xD;
           will be send to each National Coordinating Center and then centralized at regular&#xD;
           intervals subsequently in the ICDC. Follow up will be required twice a year. For each&#xD;
           case of CML, a yet to be fixed sum of money will be transferred from the ICDC to the&#xD;
           National Coordinating Center at notification of the case and when complete data transfer&#xD;
           will be performed.&#xD;
&#xD;
           To avoid extra work, data already computerized will be accepted if it fulfilled the&#xD;
           requirements of ethics, confidentiality and partnership rules as mentioned in paragraph&#xD;
           7.&#xD;
&#xD;
           When available agreement between parties, data may come from case report form of&#xD;
           patients included in clinical studies or other Registries. Data will be sent by regular&#xD;
           mail, fax or electronic file by the national coordinators to the ARC of the study at the&#xD;
           ICDC. Data received by mail will be transferred by copy using disks (CD-Rom or external&#xD;
           disk) to the data-manager and destroyed from the computer with mail box. Data will be&#xD;
           entered in a Microsoft ACCESS database in the ICDC. Data base will be implemented in a&#xD;
           PC (I) (Windows) located in a room dedicated for the purpose of the work. A second PC&#xD;
           (II) in the same place will be used for duplication, backup, quality control and&#xD;
           analysis of the data. None of these 2 PCs will offer connections such as Internet, or&#xD;
           Intranet. The use of an electronic case Report form (e-CRF) is not planned. A secure&#xD;
           access building and rooms of the ICDC is organized; specific password and login for the&#xD;
           computers are used. At regular interval a secure storage of the data will be performed&#xD;
           and located in the secure IDCD room organized for this purpose. Access to the data will&#xD;
           be restricted to the coordinator of the study, the ARC, the data manager, the&#xD;
           biostatistician, and Health Authorities, if needed.&#xD;
&#xD;
        6. Study duration and organization The expected start date is August 1, 2009. The planned&#xD;
           study duration is about 5 years. Study prolongation will depend on the funding linked to&#xD;
           the effective participation of the centres in the study.&#xD;
&#xD;
        7. Analysis of the data Data will be analysed using mainly SAS software (SAS institute,&#xD;
           CARY, NC, USA). Final analyses will be provided within 5 years from start of the study.&#xD;
           Analysis will be mainly descriptive. Date of inclusion in the study is defined as the&#xD;
           date of reception of the notification of case by the ICDC. For the purpose of&#xD;
           descriptive analysis, all parameters will be analysed at regular intervals: number of&#xD;
           registered cases, baseline characteristics, follow-up and outcome variables. Categorical&#xD;
           data will be presented with frequency, percentage and 95 % confidence interval.&#xD;
           Quantitative variable will be presented with median and range, mean and standard&#xD;
           deviation when relevant. Survival data and issue to events (time to response or&#xD;
           side-effects, loss and duration of response…); will be analysed by the Kaplan Meier and&#xD;
           competing risks methods. For prognosis factors identification, exploratory analyses will&#xD;
           be performed as appropriate. The final statistical plan will be validated by the&#xD;
           steering committee and the scientific committee.&#xD;
&#xD;
           Reports will be provided every 6 months and by the end of the study by the ARC, the data&#xD;
           manager, the biostatistician and Dr F. Millot, coordinator of the study. These reports&#xD;
           will be sent to the national coordinators and to the participants. Results could be&#xD;
           presented in Workshops, meetings and could be published with the agreement of the&#xD;
           steering and scientific committees. All reports and publications will remain anonymous.&#xD;
&#xD;
        8. Number of Patients :&#xD;
&#xD;
           A proximately 100 to 150 patients per year are expected. As the number of cases of&#xD;
           children and adolescent with CML being low, no strict calculation was made. The&#xD;
           objective is to collect a maximum of cases to improve the power of the study.&#xD;
&#xD;
        9. Ethical Considerations The children, according to their age, and their parents will be&#xD;
           informed about the study and its procedures, according to the European policy regarding&#xD;
           collection and transfer data for research purpose. Informed consent (parents and, when&#xD;
           possible, children) will have to be provided.&#xD;
&#xD;
      Anonymized data will be collected and presented in this study. Rules will be in accordance&#xD;
      with the Principles and Guideline of the European Community concerning clinical studies and&#xD;
      data collection and the French Law &quot;Informatique, fichiers et liberté&quot; (January 6, 1978,&#xD;
      updated.It is the responsibility of each national coordinator to provide insurance concerning&#xD;
      the participation of the members of his groups according these rules and the local rules&#xD;
      required by his own country.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients less than 18 years of age with newly diagnosed Philadelphia positive and/or&#xD;
        bcr-abl positive CML are eligible whatever the phase of the disease, the type of treatment&#xD;
        and the enrollment or not in a clinical study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients less than 18 years of age&#xD;
&#xD;
          -  diagnosed Philadelphia positive and/or BCR-ABL positive Chronic Myeloid Leukemia (CML)&#xD;
             all phases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients more than 18 years of age at diagnosis of CML&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic MILLOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic MILLOT, MD</last_name>
    <phone>+33 (0)5 49 44 30 78</phone>
    <email>f.millot@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo DIBAR, Prof.</last_name>
      <email>eduardo.dibar@hiba.org.ar</email>
    </contact>
    <investigator>
      <last_name>Eduardo DIBAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's and children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather TAPP, Prof.</last_name>
      <email>heather.tapp@health.sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Heather TAPP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Cancer Research Institute</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mchael DWORZAK, Prof.</last_name>
      <email>michael.dworzak@ccri.at</email>
    </contact>
    <investigator>
      <last_name>Michael DWORZAK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Center for Pediatric Oncology and Hematology</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia SAVVA, MD</last_name>
      <email>n_savva@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Natalia SAVVA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Françoise DRESSE, Prof.</last_name>
      <email>marie-francoise.dresse@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Marie Françoise DRESSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara DE MOERLOOSE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice FERSTER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlies BEKAERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia Pediatrica</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lucia LEE, MD</last_name>
      <email>mlucialee@ig.com.br</email>
    </contact>
    <investigator>
      <last_name>Maria Lucia LEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Roberto Del Rio</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam CAMPBELL BULL, MD</last_name>
      <email>myriamcampbellb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Myriam CAMPBELL BULL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li CHI KONG, Prof.</last_name>
      <email>ckli@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Li CHI KONG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Zagreb</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordana JAKOVLJEVIC</last_name>
      <phone>+385914600152</phone>
      <email>gordanajakovljevic@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gordana JAKOVLJEVIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles University Motol</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr SEDLACEK, PhD</last_name>
      <phone>+420 22443 6552</phone>
      <email>Petr.Sedlacek@fnmotol.cz</email>
    </contact>
    <contact_backup>
      <last_name>Ales LUKS</last_name>
      <email>ales.luks@lfmotol.cuni.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Petr SEDLACEK, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitte LAUSEN, MD</last_name>
      <phone>45 3545 8177</phone>
      <email>Birgitte.Lausen@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Birgitte LAUSEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Center CIC 1402</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violaine GOYEAU, Master</last_name>
      <phone>+33 (0)5 49 44 30 57</phone>
      <email>violaine.goyeau@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Joelle GUILHOT, PhD</last_name>
      <phone>+33 (0)5 49 44 46 89</phone>
      <email>j.guilhot@chu-poitiers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frederic MILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meinolf SUTTORP, Prof.</last_name>
      <email>meinolf.suttorp@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Meinolf SUTTORP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agia Sophia Children's Hospital</name>
      <address>
        <city>Athen</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vassilios PAPADAKIS, MD</last_name>
      <email>vpapadak@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Vassilios PAPADAKIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keio University School of Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shimada HIROYUKI, MD PhD</last_name>
      <email>hshimada@a5.keio.jp</email>
    </contact>
    <investigator>
      <last_name>Shimada HIROYUKI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint George Hospital University Medical Centre</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farah ROULA, MD</last_name>
      <email>roula.fs@dm.net.lb</email>
    </contact>
    <investigator>
      <last_name>Farah ROULA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eveline DE BONT, Prof.</last_name>
      <email>e.de.bont@bkk.umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Eveline DE BONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University Department</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof KALWAK, PhD</last_name>
      <phone>+48717703170</phone>
      <email>krzysztof.kalwak@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Malgorzata Janeczko</last_name>
      <email>ml.janeczko@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Krzysztof KALWAK, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Bratislava</city>
        <zip>813 72</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia KAISEROVA, Prof</last_name>
      <email>emilia.kaiserova@fmed.uniba.sk</email>
    </contact>
    <investigator>
      <last_name>Emilia KAISEROVA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uludag University, Medical Faculty</name>
      <address>
        <city>Görükle</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adalet M GÜNEŞ, MD</last_name>
      <email>adaletm@uludag.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Adalet M GÜNEŞ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Japan</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment outcome</keyword>
  <keyword>side effects</keyword>
  <keyword>Protein Kinase Inhibitors</keyword>
  <keyword>pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

